Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen

Vaccine

Volumn 20, Issue 27-28, 2002, Pages 3389-3398

  O'Hagan, D T ^a   Singh, M ^a   Kazzaz, J ^a   Ugozzoli, M ^a   Briones, M ^a   Donnelly, J ^a   Ott, G ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CpG; HIV; MF59 adjuvant

Indexed keywords

DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN G2A; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OLIGONUCLEOTIDE; POLYGLACTIN; PROTEIN P55; UREA; VIRUS ANTIBODY; VIRUS PROTEIN; WATER OIL CREAM;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW; CONTROLLED STUDY; DENDRITIC CELL; DNA SEQUENCE; EMULSION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOSTIMULATION; MICROPARTICLE ENZYME IMMUNOASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADSORPTION; AIDS VACCINES; ANIMALS; ANTIGEN PRESENTATION; DENDRITIC CELLS; DRUG SYNERGISM; EMULSIONS; FEMALE; GENE PRODUCTS, GAG; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNOGLOBULIN G; LACTIC ACID; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; POLYGLYCOLIC ACID; POLYMERS; PROTEIN PRECURSORS; SOLUBILITY;

EID: 0037056053     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00272-4     Document Type: Article

References (44)

1. Tokunaga T., Yamamoto H., Shimada S.et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Part I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72(4):1984;955-962.
2. Messina J.P., Gilkeson G.S., Pisetsky D.S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 147(6):1991;1759-1764.
3. Krieg A.M., Yi A.K., Matson S.et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374(6522):1995;546-549.
4. Bird A.P. CpG islands as gene markers in the vertebrate nucleus. Trends Genet. 3:1987;342-347.
5. Janeway C.A., Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin. Immunol. 10(5):1998;349-350.
6. Matzinger P. Tolerance, danger, and the extended family. Ann. Rev. Immunol. 12:1994;991-1045.
7. Sparwasser T., Koch E.S., Vabulas R.M.et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28(6):1998;2045-2054.
8. Manzel L, Strekowski L, Ismail F, Smith JE, Macfarlane O. Antagonism of immunostimulatory CpG oligonucleotides by 4-aminoquinolines and other weak bases: Mechanistic studies, J Pharmacol Exp Ther, 1999.
9. Hemmi H., Takeuchi O., Kawaii T.et al. A toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
10. Chu W., Gong X., Li Z.et al. DNA PKcs is required for activation of innate immunity by immunostimulatory DNA. Cell. 103:2000;909-918.
11. Hacker H., Mischak H., Miethke T.et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17(21):1998;6230-6240.
12. Davis H.L., Weeratna R., Waldschmidt T.J.et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen [published erratum appears in J Immunol 1 March 1999;162(5):3103]. J. Immunol. 160(2):1998;870-876.
13. Sun S., Kishimoto H., Sprent J. DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J. Exp. Med. 187(7):1998;1145-1150.
14. Brazolot Millan C.L., Weeratna R., Krieg A.M., Siegrist C.A., Davis H.L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. U.S.A. 95(26):1998;15553-15558.
15. Broide D., Schwarze J., Tighe H.et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J. Immunol. 161(12):1998;7054-7062.
16. Hartmann G., Weiner G.J., Krieg A.M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 96(16):1999;9305-9310.
17. Baner M., Heeg K., Wagner H., Lipford G.B. DNA activates human immune cells through a CpG sequence-dependent manner. Immunology. 97(4):1999;699-705.
18. Hartmann G., Weeratna R.D., Ballas Z.K.et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164(3):2000;1617-1624.
19. Davis H.L., Suparto I.I., Weeratna R.R.et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 18(18):2000;1920-1924.
20. Davis H. In: Proceedings of the Third Annual Conference on Vaccine Research. Washington (DC): IAVI, 2000.
21. Klinman D.M., Barnhart K.M., Conover J. CpG motifs as immune adjuvants. Vaccine. 17(1):1999;19-25.
22. Dupuis M., Murphy T.J., Higgins D.et al. Dendritic cells intemalize vaccine adjuvant after intramuscular injection. Cell Immunol. 186(1):1998;18-27.
23. O'Hagan D.T., Ugozzoli M., Barackman J.et al. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HTV-1. Vaccine. 18(17):2000;1793-1801.
24. Kazzaz J., Neidleman J., Singh M., Ott G., O'Hagan D.T. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HTV-1. J. Control Release. 67(2-3):2000;347-356.
25. Weeratna R.D., McCluskie M.J., Xu Y., Davis H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 18(17):2000;1755-1762.
26. Ott G, Barchfeld GL, Chemoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59: Design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell MF, Newman MJ, editors. Vaccine Design: The Subunit and Adjuvant Approach, New York: Plenum Press. p. 277-96.
27. Lindblad E., Elhay M., Silva R., Appelberg R., Andersen P. Adjuvant modulation of immune responses to tuberculosis vaccines. Infect. Immun. 65(2):1997;623-629.
28. Neidleman JA, Ott G, O'Hagan D, editors. Mutant Heat-Labile Enterotoxins as Adjuvants for CTL Indction. Totowa (NJ): Humana Press, 2000. p. 327-36.
29. Valensi J.P., Carison J.R., Van Nest G.A. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol. 153(9):1994;4029-4039.
30. Chai J., Vendetti S., bartok I.et al. Critical role of costimulation in the activation of naive antigen-specific TCR transgenic CD8+ T cells in vitro. J. Immunol. 163(3):1999;1298-1305.
31. King C.A., Mueller Hoenger R., Cleary M.et al. Interleukin-4 acts at the locus of the antigen-presenting dendritic cell to counter regulate cytotoxic CD8+ T cell responses. Nature Med. 7(7):2001;206-214.
32. Valenzuela P., Medina A., Rutter W.J., Ammerer G., Hall B.D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 298(5872):1982;347-350.
33. Moldoveanu Z., Love-Homan L., Huang W.Q., Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 16(11-12):1998;1216-1224.
34. Aderem A., Ulevitch R. Toll-like receptors in the induction of the innate immune response. Nature. 406:2000;782-787.
35. Krieg A.M. Immune effects and mechanisms of action of CpG motifs. Vaccine. 19:2001;68-622.
36. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392(6673):1998;245-252.
37. Chu R.S., Askew D., Harding C.V. CpG DNA switches on Thi immunity and modulates antigen-presenting cell function. Current Topics Microbiol Immunol. 247:2000;199-210.
38. Hacker H., Vabulas R., Takeuchi O., Hoshino K., Akira S., Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med. 192(4):2000;595-600.
39. Stacey K.J., Sweet M.J., Hume D.A. Macrophages ingest and are activated by bacterial DNA. J. Imnunol. 157(5):1996;2116-2122.
40. Sparwasser T., Miethke T., Lipford G.et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur. J. Immunol. 27(7):1997;1671-1679.
41. Yi A.K., Tuetken R., Redford T., Waldschmidt M., Kirsch J., Krieg A.M. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J. Immunol. 160(10):1998;4755-4761.
42. Dupuis M., Denis-Mize K., Woo C.et al. Distribution of DNA vaccines deterrnines their immunogenicity after intramuscular injection in mice. J. Immunol. 165(5):2000;2850-2858.
43. Singh M., Briones M., Ott G., O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA. 97(2):2000;811-816.
44. Denis-Mize K.S., Dupuis M., MacKichan M.L.et al. Plasmid DNA adsorbed onto PLG-CTAB microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 7:2000;2105-2112.